Compounds

A compound or a pharmaceutically acceptable salt thereof having the structure of Formula (I-4)

• wherein
• R1 is selected from the group consisting of H, C1-3alkyl, and —C(O)—C1-3alkyl;
• and
• R2 and R3 together with the carbon to which they are attached form a 4-, 5- or 6-membered saturated ring, which ring
• optionally contains one heteroatom ring member selected from N or O, and
• is optionally substituted with one substituent of -L-K, wherein
• L is selected from the group consisting of C(O), CH2, and S(O)2, and
• K is selected from the group consisting of C1-3alkyl, phenyl, and C3-6cycloalkyl;
• or R1 and R2 together with the nitrogen and carbon to which they are attached form a 6-membered saturated ring, which ring
• optionally contains one or two additional heteroatom ring members independently selected from the group consisting of N, O, C(O), S, S(O), and S(O)2, and
• is optionally substituted with one or more substituents independently selected from the group consisting of OH, halo, NR1aR1b, COOH, and —Y—Rc, wherein
• Y is absent or is selected from the group consisting of C(O), S(O)2, —C(O)—C(O)—, and CH2, and
• Rc is selected from the group consisting of
• C1-5alkyl optionally substituted with one or more substituents independently selected from the group consisting of NR2aR2b, C3-6 cycloalkyl, and —COOH,
• C1-3haloalkyl,
• C1-3alkoxyl,
• NR3aR3b,
• —(CH2)p—C(O)—O—C1-3alkyl, wherein p is 1, 2, or 3 and the —(CH2)p— is optionally substituted by one or more methyl,
• —(CH2)q—C3-6 cycloalkyl, wherein q is 1, 2, or 3, the cycloalkyl is optionally substituted with NR4aR4b, and the —(CH2)q— is optionally substituted by one or more methyl, and
• heterocyclyl optionally substituted with one or more substituents independently selected from the group consisting of halo and NR5aR5b,
• wherein R1a, R1b, R2a, R2b, R3a, R3b, R4a, R4b, R5a, and R5b are independently H or C1-3alkyl;
• and
• R3 is H;
• each occurrence of R4 is independently H or D;
• X is absent or is selected from the group consisting of
• —O—,
• —NH—, and
• —N(C1-3 alkyl)-,
• n is 1 or 2;
• or
• X is —O—CH2-bicyclo[1.1.1]pentanyl-CH2—O— and n is 0;
• and
• A is unsubstituted thiophenyl, or
• A is
• wherein
• R5 and R9 are independently H or halo,
• Z′ is N or CR6,
• Z is N or CR8,
• wherein R6 and R8 are independently selected from the group consisting of H, CN, halo, C1-3alkyl, C1-3haloalkyl, —S(O)2—C1-3alkyl and —S(O)—C1-3alkyl, and
• V is CR7, wherein R7 is -Q-(CH2)m—W, wherein
• Q is O, N, or CH2,
• m is 0 or 1, and
• W is pyridyl, and
• wherein said pyridyl is optionally substituted with one or more substituents independently selected from the group consisting of C1-3haloalkyl, CN, halo, and C1-5 alkyl.